Provention Bio’s $95.7 Million Common Stock Offering

Lowenstein Sandler represented Provention Bio, Inc. in the offering.

Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, completed its underwritten public offering, which is expected to gross $95.7 million (before deducting underwriting discounts and commissions and other offering expenses payable by Provention Bio.). The offering is expected to close on or about June 22, 2020, subject to customary closing conditions.

Provention Bio intends to use its net proceeds from the public offering for general corporate purposes, including the continued funding of clinical development, regulatory, and manufacturing activities.

The Lowenstein deal team advising Provention Bio included Michael J. Lerner (Picture), Steven M. Skolnick, James C. Shehan, Sarah P. Cole, and Timothy N. MacKay.

Involved fees earner: Sarah Cole – Lowenstein Sandler LLP; Michael Lerner – Lowenstein Sandler LLP; Timothy MacKay – Lowenstein Sandler LLP; James Shehan – Lowenstein Sandler LLP; Steven Skolnick – Lowenstein Sandler LLP;

Law Firms: Lowenstein Sandler LLP;

Clients: Provention Bio, Inc.;

Author: Ambrogio Visconti